- FDA committee recommends approval of OraSure's in-home HIV test
- FDA to review Achillion's HCV drug on fast track basis
- FDA unclear on link between Novartis' MS drug Gilenya, patient deaths
- Stiefel's Fabior foam approved for treating acne
- Ohr Pharmaceutical wins fast track designation for wet AMD product candidate
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
Saturday, February 04 2012 | Comments
What's This?
The Food and Drug Administration agreed to allow Bayer HealthCare LLC to proceed with the company's expanded access program to provide the investigational drug radium-223 chloride to patients with castration-resistant prostate cancer/hormone-refractory prostate cancer with symptomatic bone metastases. An expanded access program permits, under certain circumstances, the use of an investigational drug in patients with a serious disease or condition who cannot participate in a controlled clinical trial of the drug.
Radium-223 chloride will now be made available to patients through qualified clinical sites that participate in the expanded access program.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- Researchers evaluate predictors of re-excision, residual disease in women with close, positive margins following partial mastectomy
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Men with biopsy Gleason score 7, tertiary grade 5 disease face similar risk of PSA recurrence as men with higher Gleason score disease, study data suggest
- PSA screening controversy increases with release of mortality studies with conflicting results, modest benefits
- Serial prostate biopsies linked to increased risk of erectile dysfunction, study shows
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- Radiation therapy for prostate cancer raises bladder, rectal cancer risk, study indicates
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Study supports use of adenoma detection rate as quality indicator for colonoscopy screening
- ACE inhibitors, ARBs may reduce risk of nonmelanoma skin cancer in high-risk patients, researchers report
